These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33285430)

  • 1. An insight into the interaction between α-ketoamide- based inhibitor and coronavirus main protease: A detailed in silico study.
    Banerjee S
    Biophys Chem; 2021 Feb; 269():106510. PubMed ID: 33285430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
    Awoonor-Williams E; Abu-Saleh AAA
    Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Mechanism of Covalent Inhibition: Simulating the Binding Free Energy of α-Ketoamide Inhibitors of the Main Protease of SARS-CoV-2.
    Mondal D; Warshel A
    Biochemistry; 2020 Dec; 59(48):4601-4608. PubMed ID: 33205654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QM/QM studies for Michael reaction in coronavirus main protease (3CL Pro).
    Taranto AG; Carvalho P; Avery MA
    J Mol Graph Model; 2008 Oct; 27(3):275-85. PubMed ID: 18567519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition Mechanism of SARS-CoV-2 Main Protease with Ketone-Based Inhibitors Unveiled by Multiscale Simulations: Insights for Improved Designs*.
    Ramos-Guzmán CA; Ruiz-Pernía JJ; Tuñón I
    Angew Chem Int Ed Engl; 2021 Dec; 60(49):25933-25941. PubMed ID: 34581471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuning Proton Transfer Thermodynamics in SARS-CoV-2 Main Protease: Implications for Catalysis and Inhibitor Design.
    Zanetti-Polzi L; Smith MD; Chipot C; Gumbart JC; Lynch DL; Pavlova A; Smith JC; Daidone I
    J Phys Chem Lett; 2021 May; 12(17):4195-4202. PubMed ID: 33900080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cysteine focused covalent inhibitors against the main protease of SARS-CoV-2.
    Paul AS; Islam R; Parves MR; Mamun AA; Shahriar I; Hossain MI; Hossain MN; Ali MA; Halim MA
    J Biomol Struct Dyn; 2022 Mar; 40(4):1639-1658. PubMed ID: 33047658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
    Achilonu I; Iwuchukwu EA; Achilonu OJ; Fernandes MA; Sayed Y
    J Mol Graph Model; 2020 Dec; 101():107730. PubMed ID: 32920239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
    Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
    Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based lead optimization of herbal medicine rutin for inhibiting SARS-CoV-2's main protease.
    Huynh T; Wang H; Luan B
    Phys Chem Chem Phys; 2020 Nov; 22(43):25335-25343. PubMed ID: 33140777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiscale Simulations of the Covalent Inhibition of the SARS-CoV-2 Main Protease: Four Compounds and Three Reaction Mechanisms.
    Grigorenko BL; Polyakov IV; Khrenova MG; Giudetti G; Faraji S; Krylov AI; Nemukhin AV
    J Am Chem Soc; 2023 Jun; 145(24):13204-13214. PubMed ID: 37294056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases.
    Sivakumar D; Stein M
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34071582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,2,4 triazolo[1,5-a] pyrimidin-7-ones as novel SARS-CoV-2 Main protease inhibitors: In silico screening and molecular dynamics simulation of potential COVID-19 drug candidates.
    Kavitha K; Sivakumar S; Ramesh B
    Biophys Chem; 2020 Dec; 267():106478. PubMed ID: 33022567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation.
    Keretsu S; Bhujbal SP; Cho SJ
    Sci Rep; 2020 Oct; 10(1):17716. PubMed ID: 33077821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.
    Lu IL; Mahindroo N; Liang PH; Peng YH; Kuo CJ; Tsai KC; Hsieh HP; Chao YS; Wu SY
    J Med Chem; 2006 Aug; 49(17):5154-61. PubMed ID: 16913704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.
    Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R
    J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational analysis of the interactions between Ebselen and derivatives with the active site of the main protease from SARS-CoV-2.
    Rieder GS; Nogara PA; Omage FB; Duarte T; Dalla Corte CL; da Rocha JBT
    Comput Biol Chem; 2023 Dec; 107():107956. PubMed ID: 37748316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.